The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding ...
Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of ...
The MARS2 trial put the mesothelioma treatment community off its axis, at least in terms of whether these patients should undergo surgery. The phase III study showed that extended pleurectomy ...
Dr. Leah Backhus discusses how the minimally invasive chemotherapy technique offers a new option for pleural mesothelioma ...
SMART combines high-dose IMRT with extrapleural pneumonectomy, showing improved survival for malignant pleural mesothelioma patients. The trial demonstrated a median overall survival of 24.4 months, ...
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer ...
Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed. The addition of surgery ...
Researchers have developed a new method for filling and sealing pleural cavities. The process consists of injecting polyurethane foams into the lungs with a self-expanding and self-modelling capacity ...
Please provide your email address to receive an email when new articles are posted on . Surgery for managing complicated pleural space infections had better outcomes than fibrinolytic therapy, ...
The median survival of patients undergoing trimodality therapy is 1–2 years, but some patients (19%) can live for 3–14 years. To improve outcomes and survival, the focus of clinical research over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results